COMMUNIQUÉ FROM EXTRAORDINARY GENERAL MEETING FOR GENOVIS AB (PUBL) NOVEMBER 19, 2013
The Extraordinary General Meeting decided upon a rights issue to existing shareholders in which three (3) existing shares entitle the holder to subscription for one (1) new share at a subscription price of SEK 4.50/ share. The share capital could increase by a maximum of SEK 2,104,100.80 through the issuance of up to 5,260,252 shares.
Timetable for new issue
Nov. 25, 2013 Last trading day for Genovis share, including subscription rights for new issue.
Nov. 28, 2013 Record date for participation in the new issue; shareholders registered in Genovis’ share register on this day receive subscription rights for participation in the new issue.
Dec. 2 – Dec. 16, 2013 Subscription period. Subscription with preferential rights through cash payment during the subscription period. Shareholders may report their intention to subscribe throughout the subscription period.
The Extraordinary General Meeting resolve to authorize the Board, provided that the rights issue for a maximum of 5,260,252 shares is fully subscribed, on one or more occasions, to decide on the issuance of a total of a maximum of 1,350,000 shares in the Company with or without preferential rights for the Companyʼs shareholders. The subscription price will be four Swedish kronor and fifty öre (SEK 4.50), payment for subscribed shares shall be made in cash, and the Board will have the option to permit set-offs retroactively. This authorization will be valid for the period ending on January 20, 2014.
The reason for any deviation from shareholdersʼ preferential rights is to be able to take advantage of attracting interest from potential underwriters within the framework for issued underwriting guarantees.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS
Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.
Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: 46 (0)31-745 50 00